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Hepatitis C drug aﬀ ordability
The new generation of highly eﬀ ective medicines to 
treat hepatitis C oﬀ ers new hope for those aﬀ ected, 
but the high prices of these drugs block countries from 
integrating them into their treatment programmes. The 
same obstacle was present at the outset of the HIV/AIDS 
crisis until the entry of generic companies removed the 
price obstacle. 
WHO estimates that 135–150 million people are 
chronically infected with hepatitis C,1 80% of whom live 
in middle-income and low-income countries.2 A third of 
people with chronic infections will develop liver cirrhosis 
or liver cancer.3 The mortality rate due to hepatitis C is 
estimated to be 350 000 to 500 000 deaths per year. The 
disease prevalence is highest in east Asia, the Middle East, 
and north Africa. The following countries have a hepatitis 
C prevalence of more than 10%: Egypt (14%), Cameroon 
(13·8%4), Burundi (11·3%), and Mongolia (10·7%5). 
Hepatitis C is a curable disease. Not only can patients 
live without symptoms after successful treatment but 
their risk of developing hepatocellular carcinoma is also 
reduced by 75%.6 The new generation of direct-acting 
antiviral treatments, including sofosbuvir, semiprevir, 
ledipasvir, and daclatasvir, have a high cure rate of well 
over 90% and are eﬀ ective against the diﬃ  cult-to-treat 
genotypes. They have better safety proﬁ les, minimum 
drug interactions, and treatment courses of shorter 
duration. One great advantage is that these drugs are 
orally administered. Drug combinations (sofosbuvir 
with ledipasvir or daclatasvir) achieve higher cure rates 
even for patients with cirrhosis. 
However, these medicines are beyond the means of 
millions of patients. Even in the USA, a heated debate has 
occurred about the high price of sofosbuvir (US$85 000–
110 000). Some insurance companies have decided to 
ration the medicine for speciﬁ c patients. Concerns have 
also been raised about the extra burden to the public 
system (Medicaid and Medicare). In Europe, concerns 
regarding price led 13 European countries to collectively 
negotiate prices. The French health minister warned that 
such high prices would impose an unacceptable burden 
on the social security system, aﬀ ecting all users.7 
Clearly, these prices are not aﬀ ordable in developing 
countries. Some governments have begun to negotiate 
lower prices. Egypt declined to grant a patent for 
sofosbuvir and negotiated with Gilead, the producing 
company, to reach a special price of $900 for 12 weeks of 
treatment in government clinics, but treating 5 million 
patients of an estimated 11 million infected people will 
still cost Egypt $4·5 billion of the $7·22 billion total 
health budget for 2014–15.8 
The unprecedentedly high prices being charged for 
new hepatitis C drugs mean that few patients can 
beneﬁ t and no national population-wide public health 
beneﬁ t can be planned for in aﬀ ected countries; yet a 
study by Liverpool University showed that the cost to 
manufacture a 12-week course of sofosbuvir can be as 
low as $100–250.4 
Figure: Eﬀ ect of generic competition on price reduction and numbers of patients accessing ARVs in Uganda 
Reproduced from an Oxfam Brieﬁ ng Paper on generic competition, price and access to medicines,11 by permission 
of Oxfam. ARV=antiretroviral. JCRC=Joint Clinical Research Centre (the largest provider of ARVs in Uganda). 
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Several mechanisms have been used to lower the 
prices of HIV medicines, with varying degrees of success. 
Tiered pricing—ie, a system by which countries 
are divided according to their national income and a 
price is decided for each country tier—is favoured by 
pharmaceutical companies because it retains their 
control of prices. This mechanism ignores the fact that 
most of the world’s poor people live in middle-income 
countries where tiered prices are unaﬀ ordable.9
Another mechanism is voluntary licensing, whereby 
the patent-holder licences the medicines to one or more 
generic companies; however, voluntary licences are 
not transparent and usually come with conditions that 
might limit production or price reduction. In September, 
2014, Gilead issued voluntary licences to seven Indian 
generic companies to produce sofosbuvir and market 
it in 91 countries. Although this licence should induce 
generic competition and thus promise to decrease 
the price, there are limitations of its use. For example, 
the licence excludes key countries such as China and 
Brazil. The Medicines Patent Pool is an independent 
foundation to which companies surrender their 
intellectual property rights voluntarily; the foundation 
then issues sublicenses to generic companies to 
compete in the production of low-priced medicines 
in return for a royalty payment. This mechanism has 
negotiated transparent licenses that are better than 
individual companies’ licences. 
Compulsory licensing is a legal instrument that 
allows governments to break a patent and allows 
generic companies to produce and market a medicine 
at an aﬀ ordable price, paying royalties to the originator 
companies. This mechanism has been used by Thailand 
and Brazil for antiretroviral medicines. 
Other Trade Related Aspects on Intellectual Property 
Right (TRIPS) ﬂ exibilities include pre-grant opposition 
used by Indian and recently by Argentinean public 
health advocates to stop patents of medicines.10 Generic 
competition allows price competition through the entry 
of several manufacturers when patents are not granted, 
have expired, or have been voluntarily or compulsorily 
relinquished. 
In 2001, the introduction of generic medicines reduced 
the price of triple antiretroviral therapy from $12 002 
to less than $100 per patient per year, which enabled 
10 million people to receive antiretroviral treatment 
(ﬁ gure).12 The ﬁ rst generation of antiretrovirals was 
manufactured mainly by Indian companies because 
India had not at that time implemented the TRIPS. 
However, generic competition is at risk because most 
countries have implemented TRIPS and are entering 
into free-trade agreements that make it diﬃ  cult to use 
TRIPS ﬂ exibilities, such as compulsory licensing. 
Learning from the situation with HIV, sustained 
aﬀ ordable medicines for hepatitis C cannot be achieved 
without generic competition. Countries can legally 
use TRIPS ﬂ exibilities, such as compulsory licensing, to 
enable generic competition. Other mechanisms such 
as tiered pricing and voluntary licensing must allow 
generic competition without conditions.
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